Tue, May 13, 9:30 PM (30 days ago)
**ClearPoint Neuro, Inc. (CLPT) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $8.5 million, up 11% from Q1 2024 ($7.6 million). - Product revenue: $5.3 million, up 46%. - Service revenue: $3.2 million, down 20%. - **Gross Profit:** $5.1 million, up 13% from Q1 2024 ($4.5 million). - **Gross Margin:** 60%, up from 59% in Q1 2024. - **Net Loss:** $6.0 million, up 45% from Q1 2024 ($4.1 million). - **Cash Flow:** Negative $7.7 million, primarily due to operating losses and equipment acquisitions. **Profit Margins and Earnings:** - **Operating Loss:** $6.2 million, up from $4.2 million in Q1 2024. - **Earnings per Share (EPS):** -$0.22, down from -$0.16 in Q1 2024. **Cash Flow and Liquidity:** - **Cash and Cash Equivalents:** $12.4 million, down from $20.1 million in Q1 2024. - **Cash Used in Operations:** $6.2 million, up from $3.8 million in Q1 2024. - **Cash Used in Investing Activities:** $0.2 million, primarily for equipment acquisitions. - **Cash Used in Financing Activities:** $1.4 million, primarily for tax payments related to equity awards. **Trends and Uncertainties:** - **Revenue Growth:** Driven by increased product sales, particularly in neurosurgery navigation and therapy. - **Cost Increases:** Higher research and development, sales and marketing, and general and administrative expenses. - **Macroeconomic Factors:** Inflation, monetary policy changes, and global economic conditions may impact costs and customer spending. - **Customer Dependence:** A few customers represent a significant portion of sales and accounts receivable. - **Legal Proceedings:** A lawsuit related to an adverse outcome in a surgical procedure using the ClearPoint system. **Future Operations and Impact:** - **Product Development:** Continued investment in ClearPoint system enhancements and new product offerings. - **Market Expansion:** Growth in biologics and drug delivery services, dependent on customer relationships and trial success. - **Funding:** Reliance on equity offerings and notes payable for financing operations and growth. - **Cash Forecast:** Existing cash balances expected to support operations for at least the next twelve months. **Ticker:** CLPT **Full Name:** ClearPoint Neuro, Inc.